News : Kayentis software for clinical trials
Kayentis receive a third wave of funds
Kayentis, number one publisher and operator of professional handwriting recognition software for sectors with stringent requirements in terms of data sharing and security, has announced a third wave of fund raising which has led to the collection of 1.5 Million Euros.
This fund raising has been undertaken with Seventure and XAnge who already contributed towards the previous wave of fund raising allowing for the collection of a total of 6.2 million Euros at the end of 2007.
Kayentis is publishing an innovative solution based on the concept of digital paper for professional sectors with stringent requirements. The innovation resides in the capability to make a simple sheet of paper including information to be dynamically connected to an information system. In this regard, all functionalities including digitisation, data recognition and automated document classification are integrated into the template form or monitoring sheet.
The technological platform, termed FAS (Forms Automation Solution), is the result of 400 man years in R&D; it ensures a unique level of robustness, integrates a multilingual handwriting recognition mechanism as well as a series of identification and traceability functionalities for activities undertaken by users and data flows so as to fulfil requirements in terms of security in some of the most stringent commercial sectors.
Kayentis aims its products at the healthcare and pharmaceutical markets in addition to the financial service sector through vertical products constructed on the FAS platform, allowing for the implementation of complex solutions with an increased level of speed; furthermore, the intuitive nature of the solution enables this to be rolled out without requiring any change in behaviours and customs.
With a strong level of development and an international range spanning more than 50 countries, Kayentis has witnessed growth of 50% in the previous financial year. The company has, moreover, a client base spanning the globe across the healthcare sector, the pharmaceutical industry and the financial services sector.
Philippe Berna, CEO of Kayentis stated: “For Kayentis, this new fund raising operation demonstrates the success of our first two development stages. We have a comprehensive and secure solution in digitisation, processing and analysing professional forms across our two key market sectors - healthcare and financial services-, and we have rolled-out our solutions internationally, primarily in the USA. The funds collected will primarily allow for us to continue stepping up our commercial growth rate so as to consolidate our positions as market leader in the handwriting recognition and data capture market”.
Kayentis is the #1 publisher and operator of digital pen and smart paper solutions for the healthcare industry. These solutions, based on the Kayentis Digital Pen & Paper platform, combine the best of the physical and digital worlds: a very simple collection method (paper and pen) that offers the highest data reliability, plus all the advantages of electronic management (real‐time data access, precise timestamping, audit trail features, alerts, and transmission of relevant information to each stakeholder). Today, Kayentis solutions have been successfully deployed in 50 countries for more than 50,000 patients. Kayentis solutions are based on Anoto Digital Pen & Paper technology; Kayentis is one of the leading world partners of Anoto, and is certified Anoto Platinum Partner. Kayentis is a member of the Pennsylvania BIO and BIO New Jersey clusters. Kayentis is an Anoto Platinum Partner, Oracle Partner and HP Solution Business Partner.
XAnge groups together XAnge Private Equity, a portfolio management company and XAnge Capital, an industrial development capital fund (DCF). XAnge Private Equity, a subsidiary of La Banque Postale, manages 10 innovation mutual funds (representing an overall amount of more than 160 million Euros), a venture capital fund in development (XPansion, total of 50 million Euros) and the private equity compartment of Actys 2, a fund of La Banque Postale Asset Management. With a presence in Germany (Munich), XAnge is developing an increased level of investment and provides consultancy services to DVC (Deutsche Bank Group), in managing its portfolio of technological securities. XAnge Private Equity additionally provides consultancy to XAnge Capital, holding 65 million Euros, which invests in companies with postal related activities. Primarily composed of industrial companies or services focusing around La Poste Group (via the Docapost subsidiary), with Alten, Deloitte, Laser and Neopost, partner of institutional investors: Allianz France, GMF, CDC or CNP Assurances. The total amount of capital either object of consultancy or direct management by XAnge Private Equity stood at close to 350 million Euros in late 2010.
About Seventure PartnersAn active partner for companies with high potential, Seventure Partners has provided investment since 1997 in two innovative commercial sectors: Information and Communication Technologies (ICT) and Life Sciences. The team at Seventure Partners has a recognised track record and vast experience in technologies, entrepreneurship, various “Venture Capital” operations and in the specific requirements of European companies undergoing strong growth since start-up. The Life Sciences division has undertaken several operations in Europe since 2005, with the ICT division having a branch in Munich (Germany) since January 2008.